Cxcr3 expression was relatively specific to CD4+ T cells and increased following anti-PD-L1 treatment (Fig 6G), and an increase in CD4+ T cells was evident in the tumour core in anti-PD-L1-treated tumours (Fig 6H, Supplementary Fig S9G). Here, CXCR3 is linked to neoplasm.